文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Gut-liver axis in liver cirrhosis: How to manage leaky gut and endotoxemia.

作者信息

Fukui Hiroshi

机构信息

Hiroshi Fukui, Department of Gastroenterology, Endocrinology and Metabolism, Nara Medical University, Kashihara, Nara 634-8522, Japan.

出版信息

World J Hepatol. 2015 Mar 27;7(3):425-42. doi: 10.4254/wjh.v7.i3.425.


DOI:10.4254/wjh.v7.i3.425
PMID:25848468
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4381167/
Abstract

A "leaky gut" may be the cutting edge for the passage of toxins, antigens or bacteria into the body, and may play a pathogenic role in advanced liver cirrhosis and its complications. Plasma endotoxin levels have been admitted as a surrogate marker of bacterial translocation and close relations of endotoxemia to hyperdynamic circulation, portal hypertension, renal, cardiac, pulmonary and coagulation disturbances have been reported. Bacterial overgrowth, increased intestinal permeability, failure to inactivate endotoxin, activated innate immunity are all likely to play a role in the pathological states of bacterial translocation. Therapeutic approach by management of the gut-liver axis by antibiotics, probiotics, synbiotics, prebiotics and their combinations may improve the clinical course of cirrhotic patients. Special concern should be paid on anti-endotoxin treatment. Adequate management of the gut-liver axis may be effective for prevention of liver cirrhosis itself by inhibiting the progression of fibrosis.

摘要

相似文献

[1]
Gut-liver axis in liver cirrhosis: How to manage leaky gut and endotoxemia.

World J Hepatol. 2015-3-27

[2]
Leaky Gut and Gut-Liver Axis in Liver Cirrhosis: Clinical Studies Update.

Gut Liver. 2021-9-15

[3]
Gut Microbiome-based Therapeutics in Liver Cirrhosis: Basic Consideration for the Next Step.

J Clin Transl Hepatol. 2017-9-28

[4]
Gut-liver axis, cirrhosis and portal hypertension: the chicken and the egg.

Hepatol Int. 2017-5-26

[5]
Gut microbiota in alcoholic liver disease: pathogenetic role and therapeutic perspectives.

World J Gastroenterol. 2014-11-28

[6]
Intestinal Permeability Is a Mechanical Rheostat in the Pathogenesis of Liver Cirrhosis.

Int J Mol Sci. 2021-6-28

[7]
Leaky gut and the liver: a role for bacterial translocation in nonalcoholic steatohepatitis.

World J Gastroenterol. 2012-6-7

[8]
Gut Microbiota and Hepatocellular Carcinoma.

Gastrointest Tumors. 2015-5

[9]
Gut Microbiota and Bacterial Translocation in the Pathogenesis of Liver Fibrosis.

Int J Mol Sci. 2023-11-19

[10]
Endotoxaemia in the pathogenesis of cytopenias in liver cirrhosis. Could oral antibiotics raise blood counts?

Med Hypotheses. 2010-9-15

引用本文的文献

[1]
Prolonged Intestinal Ethanol Absorption and Oxidative Stress: Revisiting the Gut-Liver Axis in Alcohol-Associated Disease.

Int J Mol Sci. 2025-6-6

[2]
Origin of Hypofunctional CD103 NK Cells in Cirrhosis-Associated Ascites.

Eur J Immunol. 2025-6

[3]
Intermittent fasting and metabolic dysfunction-associated steatotic liver disease: the potential role of the gut-liver axis.

Cell Biosci. 2025-5-23

[4]
Effectiveness and safety evaluation of terlipressin in the treatment of intestinal paralysis in end-stage liver disease.

BMC Gastroenterol. 2025-4-23

[5]
Exploring the dark side of probiotics to pursue light: Intrinsic and extrinsic risks to be opportunistic pathogens.

Curr Res Food Sci. 2025-3-31

[6]
Overview of the hazardous impacts of metabolism-disrupting chemicals on the progression of fatty liver diseases.

Mol Cell Toxicol. 2025

[7]
Identification of multiple complications as independent risk factors associated with 1-, 3-, and 5-year mortality in hepatitis B-associated cirrhosis patients.

BMC Infect Dis. 2025-2-1

[8]
Intestinal and hepatic benefits of BBR-EVO on DSS-induced experimental colitis in mice.

Front Microbiol. 2024-9-4

[9]
Akkermansia muciniphila in the small intestine improves liver fibrosis in a murine liver cirrhosis model.

NPJ Biofilms Microbiomes. 2024-9-16

[10]
From Cirrhosis to the Dysbiosis (A Loop of Cure or Complications?).

Indian J Microbiol. 2024-9

本文引用的文献

[1]
Gastrointestinal dysfunction in liver cirrhosis.

World J Gastroenterol. 2014-10-28

[2]
Albumin infusion improves renal blood flow autoregulation in patients with acute decompensation of cirrhosis and acute kidney injury.

Liver Int. 2015-2

[3]
Enhancement of functional connectivity, working memory and inhibitory control on multi-modal brain MR imaging with Rifaximin in Cirrhosis: implications for the gut-liver-brain axis.

Metab Brain Dis. 2014-12

[4]
The role of rifaximine in the prevention of the spontaneous bacterial peritonitis.

Rev Med Chir Soc Med Nat Iasi. 2013

[5]
Dysbiosis contributes to fibrogenesis in the course of chronic liver injury in mice.

Hepatology. 2014-2-25

[6]
Frequency and severity of cirrhotic cardiomyopathy and its possible relationship with bacterial endotoxemia.

Dig Dis Sci. 2013-8-2

[7]
Intestinal epithelial barrier function in liver cirrhosis: an extensive review of the literature.

Liver Int. 2013-7-23

[8]
Cirrhosis, bile acids and gut microbiota: unraveling a complex relationship.

Gut Microbes. 2013-7-12

[9]
Inflammation and hepatic encephalopathy.

Arch Biochem Biophys. 2013-4-10

[10]
Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy.

PLoS One. 2013-4-2

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索